Medtronic Inc. (NYSE:MDT) shares traded down 1.4% during mid-day trading on Friday . The company traded as low as $86.25 and last traded at $86.69, with a volume of 4,420,010 shares changing hands. The stock had previously closed at $87.94.

A number of research analysts recently issued reports on the stock. Vetr upgraded shares of Medtronic from a “buy” rating to a “strong-buy” rating and set a $89.50 target price for the company in a research report on Monday, May 2nd. Credit Suisse Group AG restated a “buy” rating and set a $85.00 target price on shares of Medtronic in a research report on Tuesday, May 31st. Deutsche Bank AG restated a “buy” rating and set a $90.00 target price on shares of Medtronic in a research report on Wednesday, June 15th. Argus restated a “hold” rating on shares of Medtronic in a research report on Monday, June 20th. Finally, Zacks Investment Research upgraded shares of Medtronic from a “sell” rating to a “hold” rating in a research report on Friday, May 27th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Medtronic currently has a consensus rating of “Buy” and an average price target of $87.88.

The company has a 50-day moving average of $85.96 and a 200 day moving average of $79.17. The company has a market cap of $121.48 billion and a PE ratio of 35.12.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, May 31st. The medical technology company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.01. The business had revenue of $7.57 billion for the quarter, compared to analyst estimates of $7.49 billion. The business’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.16 EPS. Equities research analysts anticipate that Medtronic Inc. will post $4.66 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 27th. Shareholders of record on Friday, July 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date is Wednesday, July 6th. This is an increase from Medtronic’s previous quarterly dividend of $0.38.

In other Medtronic news, VP Richard Kuntz sold 49,905 shares of Medtronic stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $82.60, for a total transaction of $4,122,153.00. Following the completion of the transaction, the vice president now owns 127,647 shares in the company, valued at $10,543,642.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Geoffrey Martha sold 3,766 shares of Medtronic stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $88.26, for a total transaction of $332,387.16. The disclosure for this sale can be found here.

A number of institutional investors have made changes to their positions in MDT. Cobblestone Capital Advisors LLC NY boosted its position in shares of Medtronic by 2.1% in the fourth quarter. Cobblestone Capital Advisors LLC NY now owns 63,954 shares of the medical technology company’s stock worth $4,919,000 after buying an additional 1,331 shares during the last quarter. Commerzbank Aktiengesellschaft FI boosted its position in shares of Medtronic by 1.2% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 172,849 shares of the medical technology company’s stock worth $13,296,000 after buying an additional 1,977 shares during the last quarter. Boys Arnold & Co. Inc. boosted its position in shares of Medtronic by 107.6% in the fourth quarter. Boys Arnold & Co. Inc. now owns 21,938 shares of the medical technology company’s stock worth $1,687,000 after buying an additional 11,369 shares during the last quarter. Keating Investment Counselors Inc. boosted its position in shares of Medtronic by 0.3% in the fourth quarter. Keating Investment Counselors Inc. now owns 97,937 shares of the medical technology company’s stock worth $7,533,000 after buying an additional 275 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Medtronic by 16.4% in the fourth quarter. ProShare Advisors LLC now owns 533,056 shares of the medical technology company’s stock worth $41,003,000 after buying an additional 75,005 shares during the last quarter.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.